Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1997


1.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8

Last Modified: 1/1/1999


2.		Phase III Randomized Study of Anti-B4-Blocked Ricin as Adjuvant Therapy for Patients in CR Following Marrow Ablation and Autologous Rescue for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (Summary Last Modified 01/99)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				physiologic age 18 to 65				NCI				CLB-9254 E-C9254, CALGB-9254

Last Modified: 12/1/1992


3.		Phase I/II Study of MOAB Anti-B4/Blocked Ricin Immunoconjugate Given by Continuous Infusion in Patients with B-Cell Leukemias and Lymphomas (Summary Last Modified 12/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				physiologic 18 to 74								DFCI-90147 NCI-V91-0144

Last Modified: 10/1/1994


4.		Phase II Study of Anti-B4-bR Immunoconjugate in Relapsed/Refractory Hairy Cell Leukemia (Summary Last Modified 10/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to physiologic 64				NCI				NU-T93-0040 NCI-T93-0040O, T93-0040

Last Modified: 5/1/1997


5.		Phase II Study of Sequential Anti-B4-bR and EPOCH for Refractory B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 05/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				physiologic 18 to 65				Other				DFCI-94025 NCI-V94-0582

Last Modified: 11/1/1992


6.		Phase II Study of Anti-B4/Blocked-Ricin Conjugate in Patients with B-Cell Leukemia (Summary Last Modified 11/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				BRMP-9106B NCI-91-C-222B, NCI-T91-0166N, T91-0166

Last Modified: 9/1/1992


7.		Phase II Study of ProMACE-CytaBOM (PRED/CTX/DOX/ARA-C/BLEO/VCR/MTX) and VP-16 Followed by MOAB Anti-B4/Blocked Ricin Immunoconjugate in Adults with Low-Grade and Selected Intermediate-Grade Lymphomas (Summary Last Modified 09/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								BRMP-9110 NCI-92-C-0203

Last Modified: 7/1/1994


8.		Phase II Feasibility Study of Lineage-Specific Consolidation Therapy for Adult ALL Early in First Remission: Anti-B4-bR for B-Lineage ALL and High-Dose ARA-C for non-B-Lineage ALL (Summary Last Modified 07/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				15 and over				NCI				CLB-9311 CALGB-9311

Last Modified: 3/1/1995


9.		Phase I Study of Autologous BMT with Anti-B4-bR-Treated Bone Marrow for Acute Lymphocytic Leukemia in Remission (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 50								DFCI-90039 NCI-V94-0579

Last Modified: 7/1/1990


10.		Phase I Study of Immunotherapy with Continuous-Infusion Anti-B4/Blocked-Ricin Conjugate in Patients with B-Cell Leukemia or Lymphoma (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18 and under 65								DFCI-89078 NCI-V90-0069

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute